Literature DB >> 28963779

Automatic segmentation of the clinical target volume and organs at risk in the planning CT for rectal cancer using deep dilated convolutional neural networks.

Kuo Men1, Jianrong Dai1, Yexiong Li1.   

Abstract

PURPOSE: Delineation of the clinical target volume (CTV) and organs at risk (OARs) is very important for radiotherapy but is time-consuming and prone to inter-observer variation. Here, we proposed a novel deep dilated convolutional neural network (DDCNN)-based method for fast and consistent auto-segmentation of these structures.
METHODS: Our DDCNN method was an end-to-end architecture enabling fast training and testing. Specifically, it employed a novel multiple-scale convolutional architecture to extract multiple-scale context features in the early layers, which contain the original information on fine texture and boundaries and which are very useful for accurate auto-segmentation. In addition, it enlarged the receptive fields of dilated convolutions at the end of networks to capture complementary context features. Then, it replaced the fully connected layers with fully convolutional layers to achieve pixel-wise segmentation. We used data from 278 patients with rectal cancer for evaluation. The CTV and OARs were delineated and validated by senior radiation oncologists in the planning computed tomography (CT) images. A total of 218 patients chosen randomly were used for training, and the remaining 60 for validation. The Dice similarity coefficient (DSC) was used to measure segmentation accuracy.
RESULTS: Performance was evaluated on segmentation of the CTV and OARs. In addition, the performance of DDCNN was compared with that of U-Net. The proposed DDCNN method outperformed the U-Net for all segmentations, and the average DSC value of DDCNN was 3.8% higher than that of U-Net. Mean DSC values of DDCNN were 87.7% for the CTV, 93.4% for the bladder, 92.1% for the left femoral head, 92.3% for the right femoral head, 65.3% for the intestine, and 61.8% for the colon. The test time was 45 s per patient for segmentation of all the CTV, bladder, left and right femoral heads, colon, and intestine. We also assessed our approaches and results with those in the literature: our system showed superior performance and faster speed.
CONCLUSIONS: These data suggest that DDCNN can be used to segment the CTV and OARs accurately and efficiently. It was invariant to the body size, body shape, and age of the patients. DDCNN could improve the consistency of contouring and streamline radiotherapy workflows.
© 2017 American Association of Physicists in Medicine.

Entities:  

Keywords:  automatic segmentation; clinical target volume; deep dilated convolutional neural networks; deep learning; organs at risk; radiotherapy

Mesh:

Year:  2017        PMID: 28963779     DOI: 10.1002/mp.12602

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  73 in total

Review 1.  Artificial Intelligence in radiotherapy: state of the art and future directions.

Authors:  Giulio Francolini; Isacco Desideri; Giulia Stocchi; Viola Salvestrini; Lucia Pia Ciccone; Pietro Garlatti; Mauro Loi; Lorenzo Livi
Journal:  Med Oncol       Date:  2020-04-22       Impact factor: 3.064

2.  Improving accuracy and robustness of deep convolutional neural network based thoracic OAR segmentation.

Authors:  Xue Feng; Mark E Bernard; Thomas Hunter; Quan Chen
Journal:  Phys Med Biol       Date:  2020-03-31       Impact factor: 3.609

3.  Analyzing magnetic resonance imaging data from glioma patients using deep learning.

Authors:  Bjoern Menze; Fabian Isensee; Roland Wiest; Bene Wiestler; Klaus Maier-Hein; Mauricio Reyes; Spyridon Bakas
Journal:  Comput Med Imaging Graph       Date:  2020-12-02       Impact factor: 4.790

4.  Automated prediction of dosimetric eligibility of patients with prostate cancer undergoing intensity-modulated radiation therapy using a convolutional neural network.

Authors:  Tomohiro Kajikawa; Noriyuki Kadoya; Kengo Ito; Yoshiki Takayama; Takahito Chiba; Seiji Tomori; Ken Takeda; Keiichi Jingu
Journal:  Radiol Phys Technol       Date:  2018-08-14

5.  CT male pelvic organ segmentation using fully convolutional networks with boundary sensitive representation.

Authors:  Shuai Wang; Kelei He; Dong Nie; Sihang Zhou; Yaozong Gao; Dinggang Shen
Journal:  Med Image Anal       Date:  2019-03-21       Impact factor: 8.545

6.  Fully Automatic Left Atrium Segmentation From Late Gadolinium Enhanced Magnetic Resonance Imaging Using a Dual Fully Convolutional Neural Network.

Authors:  Zhaohan Xiong; Vadim V Fedorov; Xiaohang Fu; Elizabeth Cheng; Rob Macleod; Jichao Zhao
Journal:  IEEE Trans Med Imaging       Date:  2019-02       Impact factor: 10.048

Review 7.  Automated Radiation Treatment Planning for Cervical Cancer.

Authors:  Dong Joo Rhee; Anuja Jhingran; Kelly Kisling; Carlos Cardenas; Hannah Simonds; Laurence Court
Journal:  Semin Radiat Oncol       Date:  2020-10       Impact factor: 5.934

Review 8.  Deep learning with convolutional neural network in radiology.

Authors:  Koichiro Yasaka; Hiroyuki Akai; Akira Kunimatsu; Shigeru Kiryu; Osamu Abe
Journal:  Jpn J Radiol       Date:  2018-03-01       Impact factor: 2.374

9.  Technical Note: More accurate and efficient segmentation of organs-at-risk in radiotherapy with convolutional neural networks cascades.

Authors:  Kuo Men; Huaizhi Geng; Chingyun Cheng; Haoyu Zhong; Mi Huang; Yong Fan; John P Plastaras; Alexander Lin; Ying Xiao
Journal:  Med Phys       Date:  2018-12-07       Impact factor: 4.071

10.  AAR-RT - A system for auto-contouring organs at risk on CT images for radiation therapy planning: Principles, design, and large-scale evaluation on head-and-neck and thoracic cancer cases.

Authors:  Xingyu Wu; Jayaram K Udupa; Yubing Tong; Dewey Odhner; Gargi V Pednekar; Charles B Simone; David McLaughlin; Chavanon Apinorasethkul; Ontida Apinorasethkul; John Lukens; Dimitris Mihailidis; Geraldine Shammo; Paul James; Akhil Tiwari; Lisa Wojtowicz; Joseph Camaratta; Drew A Torigian
Journal:  Med Image Anal       Date:  2019-01-29       Impact factor: 8.545

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.